Current status of cardiac MR spectroscopy

Progress in Nuclear Magnetic Resonance Spectroscopy

Volumn 54, Issue 3-4, 2009, Pages 255-277

  Singhal, Aparna ^a   Shivkumar, Kalyanam ^a   Huda, Amir ^a,b   Thomas, M Albert ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Cardiac tissue in vivo and ex vivo; Creatine; Magnetic resonance spectroscopy; Phosphocreatine

Indexed keywords

BIOCHEMISTRY; LIPIDS; MAGNETIC FIELDS; MAGNETIC RESONANCE; PARTICLE DETECTORS; PHOSPHATES;

APPLIED MAGNETIC FIELDS; BIOCHEMICAL ANALYSIS; CARDIAC MR; CARDIAC TISSUE IN VIVO AND EX VIVO; CREATINE; CURRENT STATUS; FOURIER; FREE INDUCTION DECAYS; FUNCTION OF FREQUENCIES; FUNCTION OF TIME; LOCAL MAGNETIC FIELDS; LOCALIZATION TECHNIQUES; MR SIGNALS; MR SPECTROSCOPIES; PHOSPHOCREATINE;

MAGNETIC RESONANCE SPECTROSCOPY;

EID: 63649111119     PISSN: 00796565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnmrs.2008.10.004     Document Type: Review

References (170)

1. Beer M. Cardiac spectroscopy: techniques, indications and clinical results. Eur. Radiol. 14 6 (2004) 1034-1047
2. Bottomley P.A. MR spectroscopy of the human heart: the status and the challenges. Radiology 191 3 (1994) 593-612
3. Neubauer S. Cardiac magnetic resonance spectroscopy: potential clinical applications. Herz 25 4 (2000) 452-460
4. Sardanelli F., and Quarenghi M. MR spectroscopy of the heart. Radiol. Med. (Torino) 111 8 (2006) 1025-1034
5. Reingold J.S., McGavock J.M., Kaka S., Tillery T., Victor R.G., and Szczepaniak L.S. Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. Am. J. Physiol. Endocrinol. Metab. 289 5 (2005) E935-E939
6. Szczepaniak L.S., Dobbins R.L., Metzger G.J., Sartoni-D'Ambrosia G., Arbique D., Vongpatanasin W., Unger R., and Victor R.G. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn. Reson. Med. 49 3 (2003) 417-423
7. Kankaanpaa M., Lehto H.R., Parkka J.P., Komu M., Viljanen A., Ferrannini E., Knuuti J., Nuutila P., Parkkola R., and Iozzo P. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J. Clin. Endocrinol. Metab. 91 11 (2006) 4689-4695
8. Schar M., Kozerke S., and Boesiger P. Navigator gating and volume tracking for double-triggered cardiac proton spectroscopy at 3 Tesla. Magn. Reson. Med. 51 6 (2004) 1091-1095
9. Kozerke S., Schar M., Lamb H.J., and Boesiger P. Volume tracking cardiac 31P spectroscopy. Magn. Reson. Med. 48 2 (2002) 380-384
10. Vanhamme L., van den Boogaart A., and Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J. Magn. Reson. 129 1 (1997) 35-43
11. Bottomley P.A., and Weiss R.G. Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium. Lancet 351 9104 (1998) 714-718
12. 31P NMR spectroscopy. Science 229 4715 (1985) 769-772
13. 31P magnetic resonance spectroscopy using the rotating frame-depth selection technique. Ann. N. Y. Acad. Sci. 508 (1987) 321-332
14. 31P rotating-frame NMR. Proc. Natl. Acad. Sci. USA 84 12 (1987) 4283-4287
15. +-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation 100 18 (1999) 1847-1850
16. +-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression. J. Biol. Chem. 268 12 (1993) 8418-8421
17. Bessman S.P., and Geiger P.J. Transport of energy in muscle: the phosphorylcreatine shuttle. Science 211 4481 (1981) 448-452
18. Neubauer S. The failing heart - an engine out of fuel. N. Engl. J. Med. 356 11 (2007) 1140-1151
19. 31P-SLOOP magnetic resonance spectroscopy. J. Am. Coll. Cardiol. 40 7 (2002) 1267-1274
20. Starling R.C., Hammer D.F., and Altschuld R.A. Human myocardial ATP content and in vivo contractile function. Mol. Cell. Biochem. 180 1-2 (1998) 171-177
21. 31P spectroscopic chemical shift imaging. Eur. Radiol. 15 2 (2005) 319-323
22. Kuno S., Ogawa T., Katsuta S., and Itai Y. In vivo human myocardial metabolism during aerobic exercise by phosphorus-31 nuclear magnetic resonance spectroscopy. Eur. J. Appl. Physiol. Occup. Physiol. 69 6 (1994) 488-491
23. Conway M.A., Bristow J.D., Blackledge M.J., Rajagopalan B., and Radda G.K. Cardiac metabolism during exercise measured by magnetic resonance spectroscopy. Lancet 2 8612 (1988) 692
24. Weiss R.G., Bottomley P.A., Hardy C.J., and Gerstenblith G. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N. Engl. J. Med. 323 23 (1990) 1593-1600
25. 31P-MRS. Circulation 96 9 (1997) 2969-2977
26. Pluim B.M., Chin J.C., De Roos A., Doornbos J., Siebelink H.M., Van der Laarse A., Vliegen H.W., Lamerichs R.M., Bruschke A.V., and Van der Wall E.E. Cardiac anatomy, function and metabolism in elite cyclists assessed by magnetic resonance imaging and spectroscopy. Eur. Heart J. 17 8 (1996) 1271-1278
27. Perseghin G., De Cobelli F., Esposito A., Lattuada G., Terruzzi I., La Torre A., Belloni E., Canu T., Scifo P., Del Maschio A., Luzi L., and Alberti G. Effect of the sporting discipline on the right and left ventricular morphology and function of elite male track runners: a magnetic resonance imaging and phosphorus 31 spectroscopy study. Am. Heart J. 154 5 (2007) 937-942
28. 31P 2D CSI). Magn. Reson. Imaging 21 5 (2003) 553-559
29. 31P MR spectroscopy. Magn. Reson. Med. 56 4 (2006) 907-911
30. 31P MRS. Magn. Reson. Med. 39 5 (1998) 772-782
31. Bottomley P.A., Herfkens R.J., Smith L.S., and Bashore T.M. Altered phosphate metabolism in myocardial infarction: P-31 MR spectroscopy. Radiology 165 3 (1987) 703-707
32. 31P NMR study. Magn. Reson. Med. 5 2 (1987) 129-142
33. 31P nuclear magnetic resonance spectroscopy in patients with old myocardial infarction. Jpn. Circ. J. 56 6 (1992) 614-619
34. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86 6 (1992) 1810-1818
35. 99mTc-MIBI accumulation. Eur. J. Nucl. Med. 28 5 (2001) 602-607
36. 31P-MR-spectroscopy in humans. Eur. Radiol. 10 8 (2000) 1323-1328
37. 31P-MR Spectroscopy for the evaluation of energy metabolism in intact residual myocardium after acute myocardial infarction in humans. MAGMA 13 2 (2001) 70-75
38. D.J.E. Luney, J.A. den Hollander, W.T. Evanochko, L.L. Johnson, G.M. Pohost, Spectroscopy of human myocardial scar, in: Proc. Soc. Magn. Reson. Med., 12th Annual Scientific Meeting, 1993, p. 1091.
39. Kalil-Filho R., de Albuquerque C.P., Weiss R.G., Mocelim A., Bellotti G., Cerri G., and Pileggi F. Normal high energy phosphate ratios in "stunned" human myocardium. J. Am. Coll. Cardiol. 30 5 (1997) 1228-1232
40. 31P magnetic resonance spectroscopy. Jpn. Heart J. 39 6 (1998) 791-807
41. 1H magnetic resonance spectroscopy. J. Cardiovasc. Magn. Reson. 6 3 (2004) 685-696
42. 31P magnetic resonance spectroscopic imaging of regional high-energy phosphate metabolism in injured rat heart. Magn. Reson. Med. 39 5 (1998) 731-741
43. 31P nuclear magnetic resonance spectroscopic imaging of regions of remodeled myocardium in the infarcted rat heart. Circulation 92 12 (1995) 3527-3538
44. Wolfe C.L., Moseley M.E., Wikstrom M.G., Sievers R.E., Wendland M.F., Dupon J.W., Finkbeiner W.E., Lipton M.J., Parmley W.W., and Brasch R.C. Assessment of myocardial salvage after ischemia and reperfusion using magnetic resonance imaging and spectroscopy. Circulation 80 4 (1989) 969-982
45. 1H-magnetic resonance spectroscopy in the rabbit heart. Jpn. Circ. J. 58 9 (1994) 707-712
46. 31P magnetic resonance spectroscopy during handgrip exercise. Circulation 89 4 (1994) 1709-1716
47. 31P magnetic resonance spectroscopy. Circulation 92 1 (1995) 15-23
48. Davis K.B., Chaitman B., Ryan T., Bittner V., and Kennedy J.W. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. Coronary Artery Surgery Study. J. Am. Coll. Cardiol. 25 5 (1995) 1000-1009
49. Buchthal S.D., den Hollander J.A., Merz C.N., Rogers W.J., Pepine C.J., Reichek N., Sharaf B.L., Reis S., Kelsey S.F., and Pohost G.M. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N. Engl. J. Med. 342 12 (2000) 829-835
50. Johnson B.D., Shaw L.J., Buchthal S.D., Bairey Merz C.N., Kim H.W., Scott K.N., Doyle M., Olson M.B., Pepine C.J., den Hollander J., Sharaf B., Rogers W.J., Mankad S., Forder J.R., Kelsey S.F., and Pohost G.M. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109 24 (2004) 2993-2999
51. 31P magnetic resonance spectroscopy. Lancet 338 8773 (1991) 973-976
52. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97 25 (1998) 2536-2542
53. 31P MR spectroscopy in hypertrophic cardiomyopathy: comparison with Tl-201 myocardial perfusion imaging. Am. Heart J. 125 5 Pt 1 (1993) 1323-1328
54. 31P-magnetic resonance spectroscopy. J. Investig. Med. 45 8 (1997) 453-462
55. Beer M., Viehrig M., Seyfarth T., Sandstede J., Lipke C., Pabst T., Kenn W., Harre K., Horn M., Landschutz W., von Kienlin M., Neubauer S., and Hahn D. Cardiac energy metabolism in heart valve diseases with 31P MR spectroscopy. Radiologe 40 2 (2000) 162-167
56. Beyerbacht H.P., Lamb H.J., van Der Laarse A., Vliegen H.W., Leujes F., Hazekamp M.G., de Roos A., and van Der Wall E.E. Aortic valve replacement in patients with aortic valve stenosis improves myocardial metabolism and diastolic function. Radiology 219 3 (2001) 637-643
57. Ross Jr. J., and Braunwald E. Aortic stenosis. Circulation 38 1 Suppl. (1968) 61-67
58. Bonow R.O., Carabello B.A., Kanu C., de Leon Jr. A.C., Faxon D.P., Freed M.D., Gaasch W.H., Lytle B.W., Nishimura R.A., O'Gara P.T., O'Rourke R.A., Otto C.M., Shah P.M., Shanewise J.S., Smith Jr. S.C., Jacobs A.K., Adams C.D., Anderson J.L., Antman E.M., Faxon D.P., Fuster V., Halperin J.L., Hiratzka L.F., Hunt S.A., Lytle B.W., Nishimura R., Page R.L., and Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114 5 (2006) e84-231
59. Conway M.A., Bottomley P.A., Ouwerkerk R., Radda G.K., and Rajagopalan B. Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation 97 17 (1998) 1716-1723
60. 31P nuclear magnetic resonance evidence of skeletal muscle metabolic abnormalities in mitral stenosis. Am. J. Cardiol. 78 5 (1996) 588-591
61. 31P-MR spectroscopic imaging in hypertensive heart disease. Eur. Radiol. 16 8 (2006) 1796-1802
62. Lamb H.J., Beyerbacht H.P., van der Laarse A., Stoel B.C., Doornbos J., van der Wall E.E., and de Roos A. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 99 17 (1999) 2261-2267
63. 31P-MRS compared to echocardiographic findings in patients with hypertensive heart disease without overt systolic dysfunction-Preliminary results. Eur. J. Radiol. (2008)
64. Hardy C.J., Weiss R.G., Bottomley P.A., and Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am. Heart J. 122 3 Pt 1 (1991) 795-801
65. Masuda Y., Tateno Y., Ikehira H., Hashimoto T., Shishido F., Sekiya M., Imazeki Y., Imai H., Watanabe S., and Inagaki Y. High-energy phosphate metabolism of the myocardium in normal subjects and patients with various cardiomyopathies - the study using ECG gated MR spectroscopy with a localization technique. Jpn. Circ. J. 56 6 (1992) 620-626
66. Krahe T., Schindler R., Neubauer S., Ertl G., Horn M., and Lackner K. 31P-cardio-MR-spectroscopy in myocardial insufficiency. Rofo 159 1 (1993) 64-70
67. Nanbu T., Nakakoshi T., Yonezawa K., and Kitabatake A. Myocardial high-energy phosphate metabolism in patients with stable chronic dilated cardiomyopathy under a dobutamine-induced prolonged mild workload. Am. Heart J. 138 4 Pt 1 (1999) 641-645
68. de Roos A., Doornbos J., Luyten P.R., Oosterwaal L.J., van der Wall E.E., and den Hollander J.A. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy. J. Magn. Reson. Imaging 2 6 (1992) 711-719
69. i in patients with severe hypertrophic cardiomyopathy. Am. J. Cardiol. 80 3A (1997) 34A-40A
70. Schaefer S., Gober J.R., Schwartz G.G., Twieg D.B., Weiner M.W., and Massie B. In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease. Am. J. Cardiol. 65 16 (1990) 1154-1161
71. Auffermann W., Chew W.M., Wolfe C.L., Tavares N.J., Parmley W.W., Semelka R.C., Donnelly T., Chatterjee K., and Higgins C.B. Normal and diffusely abnormal myocardium in humans: functional and metabolic characterization with P-31 MR spectroscopy and cine MR imaging. Radiology 179 1 (1991) 253-259
72. 31P NMR spectra of the myocardium of patients with myocardial hypertrophy. J. Magn. Reson. 133 1 (1998) 232-235
73. Crilley J.G., Boehm E.A., Blair E., Rajagopalan B., Blamire A.M., Styles P., McKenna W.J., Ostman-Smith I., Clarke K., and Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J. Am. Coll. Cardiol. 41 10 (2003) 1776-1782
74. Chida K., Otani H., Kohzuki M., Saito H., Kagaya Y., Takai Y., Takahashi S., Yamada S., and Zuguchi M. The relationship between plasma BNP level and the myocardial phosphocreatine/adenosine triphosphate ratio determined by phosphorus-31 magnetic resonance spectroscopy in patients with dilated cardiomyopathy. Cardiology 106 3 (2006) 132-136
75. Neubauer S., Horn M., Cramer M., Harre K., Newell J.B., Peters W., Pabst T., Ertl G., Hahn D., Ingwall J.S., and Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96 7 (1997) 2190-2196
76. Hugel S., Horn M., de Groot M., Remkes H., Dienesch C., Hu K., Ertl G., and Neubauer S. Effects of ACE inhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction. Am. J. Physiol. 277 6 Pt 2 (1999) H2167-H2175
77. Canby R.C., Evanochko W.T., Barrett L.V., Kirklin J.K., McGiffin D.C., Sakai T.T., Brown M.E., Foster R.E., Reeves R.C., and Pohost G.M. Monitoring the bioenergetics of cardiac allograft rejection using in vivo P-31 nuclear magnetic resonance spectroscopy. J. Am. Coll. Cardiol. 9 5 (1987) 1067-1074
78. Fraser Jr. C.D., Chacko V.P., Jacobus W.E., Mueller P., Soulen R.L., Hutchins G.M., Reitz B.A., and Baumgartner W.A. Early phosphorus-31 nuclear magnetic resonance bioenergetic changes potentially predict rejection in heterotopic cardiac allografts. J. Heart Transplant. 9 3 Pt 1 (1990) 197-204
79. Bottomley P.A., Weiss R.G., Hardy C.J., and Baumgartner W.A. Myocardial high-energy phosphate metabolism and allograft rejection in patients with heart transplants. Radiology 181 1 (1991) 67-75
80. Van Dobbenburgh J.O., De Groot M.C., De Jonge N., Klopping C., Lahpor J.R., Woolley S.R., Robles De Medina E.O., and Van Echteld C.J. Myocardial high-energy phosphate metabolism in heart transplant patients is temporarily altered irrespective of rejection. NMR Biomed. 12 8 (1999) 515-524
81. Behrendt D., Ganz P., and Fang J.C. Cardiac allograft vasculopathy. Curr. Opin. Cardiol. 15 6 (2000) 422-429
82. Evanochko W.T., Buchthal S.D., den Hollander J.A., Katholi C.R., Bourge R.C., Benza R.L., Kirklin J.K., and Pohost G.M. Cardiac transplant patients response to the (31)P MRS stress test. J. Heart Lung Transplant. 21 5 (2002) 522-529
83. 31P magnetic resonance chemical shift imaging. Eur. J. Cardiothorac. Surg. 29 1 (2006) 45-49
84. Carteaux J.P., Mertes P.M., Pinelli G., Escanye J.M., Walker P., Brunotte F., Jaboin Y., Robert J., and Villemot J.P. Left ventricular contractility after hypothermic preservation: predictive value of phosphorus 31-nuclear magnetic resonance spectroscopy. J. Heart Lung Transplant. 13 4 (1994) 661-668
85. Van Dobbenburgh J.O., Lahpor J.R., Woolley S.R., de Jonge N., Klopping C., and Van Echteld C.J. Functional recovery after human heart transplantation is related to the metabolic condition of the hypothermic donor heart. Circulation 94 11 (1996) 2831-2836
86. Kober F., Caus T., Riberi A., Confort-Gouny S., LeFur Y., Izquierdo M., Ranjeva J.P., Viout P., Mesana T., Metras D., Cozzone P.J., and Bernard M. Objective and noninvasive metabolic characterization of donor hearts by phosphorous-31 magnetic resonance spectroscopy. Transplantation 74 12 (2002) 1752-1756
87. 31P MRS of heart grafts provides metabolic markers of early dysfunction. Eur. J. Cardiothorac. Surg. 28 4 (2005) 576-580
88. 31P nuclear magnetic resonance. Ann. Thorac. Surg. 54 2 (1992) 348-351
89. Brunotte F., Peiffert B., Escanye J.M., Pinelli G., Zamorano J., Walker P.M., Robert J., and Villemot J.P. Nuclear magnetic resonance spectroscopy of excised human hearts. Br. Heart J. 68 3 (1992) 272-275
90. Feygin J., Mansoor A., Eckman P., Swingen C., and Zhang J. Functional and bioenergetic modulations in the infarct border zone following autologous mesenchymal stem cell transplantation. Am. J. Physiol. Heart Circ. Physiol. 293 3 (2007) H1772-1780
91. Zeng L., Hu Q., Wang X., Mansoor A., Lee J., Feygin J., Zhang G., Suntharalingam P., Boozer S., Mhashilkar A., Panetta C.J., Swingen C., Deans R., From A.H., Bache R.J., Verfaillie C.M., and Zhang J. Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation 115 14 (2007) 1866-1875
92. Neubauer S., Horn M., Hahn D., and Kochsiek K. Clinical cardiac magnetic resonance spectroscopy - present state and future directions. Mol. Cell. Biochem. 184 1-2 (1998) 439-443
93. Nakae I., Mitsunami K., Omura T., Yabe T., Tsutamoto T., Matsuo S., Takahashi M., Morikawa S., Inubushi T., Nakamura Y., Kinoshita M., and Horie M. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J. Am. Coll. Cardiol. 42 9 (2003) 1587-1593
94. Ingwall J.S. Adaptive and Maladaptive Processes: Is Cardiac Failure a Consequence of Decreased Energy Reserve?. Circulation 87 6S Supplement 2 (1993) VII58-VII62
95. Ingwall J.S., Kramer M.F., Fifer M.A., Lorell B.H., Shemin R., Grossman W., and Allen P.D. The creatine kinase system in normal and diseased human myocardium. N. Engl. J. Med. 313 17 (1985) 1050-1054
96. Tian R., and Ingwall J.S. Energetic basis for reduced contractile reserve in isolated rat hearts. Am. J. Physiol. 270 4 Pt 2 (1996) H1207-1216
97. 1-adrenergic receptor transgenic mice. J. Mol. Cell. Cardiol. 35 4 (2003) 389-397
98. Lorentzon M., Ramunddal T., Bollano E., Soussi B., Waagstein F., and Omerovic E. In vivo effects of myocardial creatine depletion on left ventricular function, morphology, and energy metabolism - consequences in acute myocardial infarction. J. Card. Fail. 13 3 (2007) 230-237
99. Ten Hove M., Chan S., Lygate C., Monfared M., Boehm E., Hulbert K., Watkins H., Clarke K., and Neubauer S. Mechanisms of creatine depletion in chronically failing rat heart. J. Mol. Cell. Cardiol. 38 2 (2005) 309-313
100. Evanochko W.T., Reeves R.C., Sakai T.T., Canby R.C., and Pohost G.M. Proton NMR spectroscopy in myocardial ischemic insult. Magn. Reson. Med. 5 1 (1987) 23-31
101. Nakae I., Mitsunami K., Matsuo S., Matsumoto T., Morikawa S., Inubushi T., Koh T., and Horie M. Assessment of myocardial creatine concentration in dysfunctional human heart by proton magnetic resonance spectroscopy. Magn. Reson. Med. Sci. 3 1 (2004) 19-25
102. 1H magnetic resonance spectroscopy. Circ. J. 69 6 (2005) 711-716
103. 123I BMIPP myocardial scintigraphy. Acta Radiol. 48 4 (2007) 436-443
104. Obesity: preventing and managing the global epidemic. Report of a WHO consultation, World Health Organ. Tech. Rep. Ser. 894 (2000) i-xii, 1-253.
105. W.H.O, Obesity and overweight, Fact Sheet, WHO Media Center, 2006.
106. Wang Y., and Beydoun M.A. The obesity epidemic in the United States - gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol. Rev. 29 (2007) 6-28
107. Unger R.H., Zhou Y.T., and Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc. Natl. Acad. Sci. USA 96 5 (1999) 2327-2332
108. Coughlin S.S., and Rice J.C. Obesity and idiopathic dilated cardiomyopathy. Epidemiology 7 6 (1996) 629-632
109. Duflou J., Virmani R., Rabin I., Burke A., Farb A., and Smialek J. Sudden death as a result of heart disease in morbid obesity. Am. Heart J. 130 2 (1995) 306-313
110. Nakajima T., Fujioka S., Tokunaga K., Matsuzawa Y., and Tarui S. Correlation of intraabdominal fat accumulation and left ventricular performance in obesity. Am. J. Cardiol. 64 5 (1989) 369-373
111. Berkalp B., Cesur V., Corapcioglu D., Erol C., and Baskal N. Obesity and left ventricular diastolic dysfunction. Int. J. Cardiol. 52 1 (1995) 23-26
112. Alpert M.A., and Hashimi M.W. Obesity and the heart. Am. J. Med. Sci. 306 2 (1993) 117-123
113. Zhou Y.T., Grayburn P., Karim A., Shimabukuro M., Higa M., Baetens D., Orci L., and Unger R.H. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. USA 97 4 (2000) 1784-1789
114. Unger R.H., and Orci L. Lipotoxic diseases of nonadipose tissues in obesity. Int. J. Obes. Relat. Metab. Disord. 24 Suppl 4 (2000) S28-S32
115. Sharma S., Adrogue J.V., Golfman L., Uray I., Lemm J., Youker K., Noon G.P., Frazier O.H., and Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 18 14 (2004) 1692-1700
116. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 5 (2004) 1047-1053
117. Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., and Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30 6 (1972) 595-602
118. Boudina S., and Abel E.D. Diabetic cardiomyopathy revisited. Circulation 115 25 (2007) 3213-3223
119. Lopaschuk G.D. Metabolic abnormalities in the diabetic heart. Heart Fail. Rev. 7 2 (2002) 149-159
120. ATP channels in the heart. Circ. Res. 88 9 (2001) 918-924
121. Poornima I.G., Parikh P., and Shannon R.P. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ. Res. 98 5 (2006) 596-605
122. Jodalen H., Stangeland L., Grong K., Vik-Mo H., and Lekven J. Lipid accumulation in the myocardium during acute regional ischaemia in cats. J. Mol. Cell. Cardiol. 17 10 (1985) 973-980
123. van der Vusse G.J., Prinzen F.W., van Bilsen M., Engels W., and Reneman R.S. Accumulation of lipids and lipid-intermediates in the heart during ischaemia. Basic Res. Cardiol. 82 Suppl 1 (1987) 157-167
124. 1H magnetic resonance spectroscopic imaging. Magn. Reson. Med. 32 2 (1994) 175-180
125. 1H-NMR spectroscopy can accurately quantitate the lipolysis and oxidation of cardiac triacylglycerols. Biochim. Biophys. Acta 1169 2 (1993) 176-182
126. 1H spectroscopy: validation in vivo. Am. J. Physiol. 276 5 Pt 1 (1999) E977-989
127. Carley A.N., and Severson D.L. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim. Biophys. Acta 1734 2 (2005) 112-126
128. 1H-magnetic resonance spectroscopy study. Circulation 116 10 (2007) 1170-1175
129. 1H NMR chemical-shift imaging following ischemic insult. Magn. Reson. Med. 17 2 (1991) 379-389
130. 1H NMR spectroscopic imaging of myocardial triglycerides in excised dog hearts subjected to 24 hours of coronary occlusion. Circulation 93 7 (1996) 1464-1470
131. Reeves R.C., Evanochko W.T., Canby R.C., McMillin J.B., and Pohost G.M. Demonstration of increased myocardial lipid with postischemic dysfunction ("myocardial stunning") by proton nuclear magnetic resonance spectroscopy. J. Am. Coll. Cardiol. 13 3 (1989) 739-744
132. 1H NMR chemical shift imaging of the heart before and after regional ischemia. NMR Biomed. 8 2 (1995) 79-86
133. Oram J.F., Wenger J.I., and Neely J.R. Regulation of long chain fatty acid activation in heart muscle. J. Biol. Chem. 250 1 (1975) 73-78
134. 1H MR spectroscopy in the evaluation of myocardial metabolism in patients with dilated idiopathic cardiomyopathy: pilot study. Acad. Radiol. 10 10 (2003) 1187-1192
135. 1H NMR spectroscopy. Magn. Reson. Med. 30 6 (1993) 655-660
136. Richards T.L., Terrier F., Sievers R.E., Lipton M.J., Moseley M.E., and Higgins C.B. Lactate accumulation in ischemic- and anoxic-isolated rat hearts assessed by H-1 spectroscopy. Invest. Radiol. 22 8 (1987) 638-641
137. 1H-MRS in the mouse. Magn. Reson. Med. 52 5 (2004) 1029-1035
138. Andrew E.R., Bradbury A., and Eades R.G. Removal of dipolar broadening of nuclear magnetic resonance spectra of solids by specimen rotation. Nature 183 (1959) 1802
139. Garrod S., Humpfer E., Spraul M., Connor S.C., Polley S., Connelly J., Lindon J.C., Nicholson J.K., and Holmes E. High-resolution magic angle spinning 1H NMR spectroscopic studies on intact rat renal cortex and medulla. Magn. Reson. Med. 41 6 (1999) 1108-1118
140. Moka D., Vorreuther R., Schicha H., Spraul M., Humpfer E., Lipinski M., Foxall P.J., Nicholson J.K., and Lindon J.C. Biochemical classification of kidney carcinoma biopsy samples using magic-angle-spinning 1H nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 17 1 (1998) 125-132
141. 1H NMR spectroscopy. FEBS Lett. 553 1-2 (2003) 73-78
142. M.A. Thomas, A. Singhal, K. Shivkumar, unpublished.
143. Anzawa R., Bernard M., Tamareille S., Baetz D., Confort-Gouny S., Gascard J.P., Cozzone P., and Feuvray D. Intracellular sodium increase and susceptibility to ischaemia in hearts from type 2 diabetic db/db mice. Diabetologia 49 3 (2006) 598-606
144. Imahashi K., Kusuoka H., Hashimoto K., Yoshioka J., Yamaguchi H., and Nishimura T. Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury. Circ. Res. 84 12 (1999) 1401-1406
145. Askenasy N., Vivi A., Tassini M., Navon G., and Farkas D.L. NMR spectroscopic characterization of sarcolemmal permeability during myocardial ischemia and reperfusion. J. Mol. Cell. Cardiol. 33 8 (2001) 1421-1433
146. 23Na magnetic resonance imaging. Circulation 110 22 (2004) 3457-3464
147. 23Na MR imaging: comparison with cine MR imaging and delayed contrast enhancement. Radiology 221 1 (2001) 222-228
148. Greiser A., Haase A., and von Kienlin M. Improved cardiac sodium MR imaging by density-weighted phase-encoding. J. Magn. Reson. Imaging 21 1 (2005) 78-81
149. Ziegler A., Zaugg C.E., Buser P.T., Seelig J., and Kunnecke B. Non-invasive measurements of myocardial carbon metabolism using in vivo 13C NMR spectroscopy. NMR Biomed. 15 3 (2002) 222-234
150. Forder J.R., and Pohost G.M. Cardiovascular nuclear magnetic resonance: basic and clinical applications. J. Clin. Invest. 111 11 (2003) 1630-1639
151. 13C NMR. Determination of substrate preference by glutamate isotopomer distribution. J. Biol. Chem. 260 16 (1985) 9272-9279
152. 13C NMR spectroscopy. FEBS Lett. 212 1 (1987) 58-62
153. 13C NMR studies in perfused rat hearts. J. Biol. Chem. 258 22 (1983) 13785-13794
154. 13C NMR. FEBS Lett. 123 2 (1981) 315-318
155. 13C NMR spectra: metabolic flux, regulation, and compartmentation in hearts. Biophys. J. 69 5 (1995) 2090-2102
156. Lewandowski E.D., Yu X., LaNoue K.F., White L.T., Doumen C., and O'Donnell J.M. Altered metabolite exchange between subcellular compartments in intact postischemic rabbit hearts. Circ. Res. 81 2 (1997) 165-175
157. O'Donnell J.M., White L.T., and Lewandowski E.D. Mitochondrial transporter responsiveness and metabolic flux homeostasis in postischemic hearts. Am. J. Physiol. 277 3 Pt 2 (1999) H866-H873
158. O'Donnell J.M., Alpert N.M., White L.T., and Lewandowski E.D. Coupling of mitochondrial fatty acid uptake to oxidative flux in the intact heart. Biophys. J. 82 1 Pt 1 (2002) 11-18
159. Lewandowski E.D. Cardiac carbon 13 magnetic resonance spectroscopy: on the horizon or over the rainbow?. J. Nucl. Cardiol. 9 4 (2002) 419-428
160. 87Rb NMR studies of the perfused rat heart. FEBS Lett. 242 2 (1989) 215-217
161. + transport. NMR Biomed. 18 2 (2005) 111-124
162. 87Rb NMR spectroscopic study. Magn. Reson. Med. 34 5 (1995) 673-685
163. 87Rb NMR. J. Mol. Cell. Cardiol. 31 4 (1999) 817-826
164. 19F NMR spectroscopy in intact ferret hearts. Proc. Natl. Acad. Sci. USA 84 16 (1987) 6005-6009
165. 19F NMR of fluorine-labeled chelators. Proc. Natl. Acad. Sci. USA 80 23 (1983) 7178-7182
166. Murphy E., Steenbergen C., Levy L.A., Gabel S., and London R.E. Measurement of cytosolic free calcium in perfused rat heart using TF-BAPTA. Am. J. Physiol. 266 5 Pt 1 (1994) C1323-C1329
167. Xia Z., Horton J.W., Tang H., and Yang Y. Metabolic disorder in myocardiac intracellular free calcium after thermal injury. Burns 27 5 (2001) 453-457
168. 31P NMR spectroscopy. Magn. Reson. Med. 41 4 (1999) 657-663
169. Bottomley P.A., Atalar E., and Weiss R.G. Human cardiac high-energy phosphate metabolite concentrations by 1D-resolved NMR spectroscopy. Magn. Reson. Med. 35 5 (1996) 664-670
170. Bottomley P.A., Hardy C.J., and Roemer P.B. Phosphate metabolite imaging and concentration measurements in human heart by nuclear magnetic resonance. Magn. Reson. Med. 14 3 (1990) 425-434